Belpointe Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Belpointe Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-548	Closed	-$19.6K	–	1921
2023 Q1	$19.6K	Sell	548 -60	-10%	-$2.25K	﹤0.01%	2320
2022 Q4	$23K	Buy	+608	New	+$25.6K	﹤0.01%	2084
2021 Q1	–	Sell	-1,809	Closed	-$102K	–	1036
2020 Q4	$102K	Buy	+1,809	New	+$90.1K	0.01%	942
2020 Q3	–	Sell	-1,845	Closed	-$109K	–	804
2020 Q2	$109K	Buy	+1,845	New	+$103K	0.01%	698
2019 Q2	–	Sell	-1,473	Closed	-$120K	–	629
2019 Q1	$120K	Buy	+1,473	New	+$95K	0.02%	401

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Belpointe Asset Management's IONS Position: Q2 2023 in Review

Belpointe Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2023, closing a stake of 548 shares — an estimated $19.6K sold.

Belpointe Asset Management first reported a position in IONS in Q1 2019 and held it in 5 quarters. The position peaked at $120K in Q1 2019. 304 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

Belpointe Asset Management reported no remaining Ionis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 548 Ionis Pharmaceuticals shares in Q2 2023, an estimated $19.6K.
Belpointe Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 5 quarters.
Belpointe Asset Management's Ionis Pharmaceuticals position peaked at $120K in Q1 2019.
304 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.